Report addresses challenges in implementing new diagnostic tests where they are needed most
2012-06-08
(Press-News.org) Easy-to-use, inexpensive tests to diagnose infectious diseases are urgently needed in resource-limited countries. A new report based on an American Academy of Microbiology colloquium, "Bringing the Lab to the Patient: Developing Point-of-Care Diagnostics for Resource Limited Settings," describes the challenges inherent in bringing new medical devices and technologies to the areas of the world where they are needed most. Point-of-care diagnostics (POCTs) bypass the need for sophisticated laboratory systems by leveraging new technologies to diagnose infectious diseases and other health concerns at the bedside, or "point-of-care". Diagnostics account for 2% of the cost of health care, yet can affect 60-70% of treatment decisions. In resource limited areas where advanced laboratory services are not available, access to POCTs may be the difference between making a treatment decision that is informed by an accurate diagnosis versus one that is ineffective or even harmful.
Despite the urgent need for POCTs, deploying them in resource limited settings can be fraught with difficulty. "POCTs are developed by researchers and engineers and implemented by a separate group of public health professionals at a local level. There are so many variables that can make or break the effectiveness of any test, and so often the scientists and engineers developing the test are not aware of them." said Keith Klugman, who chaired the colloquium. "POCTs that perform well in testing may not function 'on the ground' in resource limited areas, where there may not be running water, electricity, or trained personnel to administer the test."
Recognizing the need to connect the scientists and engineers developing the POCTs with the health care workers implementing them, the American Academy of Microbiology convened a colloquium in September of 2011 to discuss how to develop POCTs that can be effectively integrated into resource limited settings. The participants discussed which tests were needed most urgently, features that should be incorporated in the design of the test to make it more effective in the field, and how collaborations between communities could foster an environment of success for new POCTs.
The resulting report makes recommendations in several areas. It details a list of POCTs that would make the biggest impact, for example, tests to detect drug resistance, or effectively monitor viral load in HIV patients. The report describes qualities needed in tests to be effective in resource limited settings such as minimal power requirements, simple interfaces, and integrated instructions on use and quality control protocols. Finally, it recommends changes in how POCTs are regulated, approved, and brought to market to help foster a more conducive environment for POCT development.
"POCTs can fundamentally change the quality of health care received in resource limited settings, but only if scientists, engineers, and health care professionals work together to develop simple, effective POCTs.", said Jeanne Jordan of George Washington University, one of the colloquium participants. "Bringing the Lab to the Patient: Developing Point-of Care Diagnostics for Resource Limited Settings" is a step forward in forming productive collaborations between these groups to bring POCTs to the people that need them the most.
INFORMATION:
A PDF of Bringing the Lab to the Patient: Developing Point-of-Care Diagnostics for Resource Limited Settings can be found online at: http://bit.ly/pointofcaredx
The American Academy of Microbiology is the honorific leadership group of the American Society for Microbiology. The mission of the Academy is to recognize scientific excellence, as well as foster knowledge and understanding in the microbiological sciences. A full list of Academy colloquia reports can be found at http://academy.asm.org/colloquia. For more information about the American Society for Microbiology, visit http://www.asm.org.
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-06-08
(PORTLAND, Ore.) —June 07, 2012—Eleven integrated health systems, with more than 16 million members, have combined de-identified data from their electronic health records to form the largest, most comprehensive private-sector diabetes registry in the nation.
According to a new study published today in the Centers for Disease Control and Prevention's Preventing Chronic Disease, the SUPREME-DM DataLink provides a unique and powerful resource to conduct population-based diabetes research and clinical trials.
"The DataLink will allow us to compare more prevention and ...
2012-06-08
There's new hope for development of an antibiotic that can put down a lethal bacteria or superbug linked to the deaths of hundreds of hospital patients around the world.
Researchers from the University of Alberta-based Alberta Glycomics Centre found a chink in the molecular armour of the pathogen Acinetobacter baumannii. The bacteria first appeared in the 1970's and in the last decade it developed a resistance to most antibiotics.
U of A microbiologist Mario Feldman identified a mechanism that allows Acinetobacter baumannii to cover its surface with molecules knows ...
2012-06-08
Berlin, Germany, June 7 2012: Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by €2,595,557 per 272 patients over 3 years (95 percentile range -€2,983,760 to -€2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs.
The Dutch study, which investigated 272 patients with RA starting adalimumab treatment, measured ...
2012-06-08
Berlin, Germany, June 7 2012: Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumour necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid arthritis (RA) respectively, compared to not using anti-TNF therapies (adjusting for background use of methotrexate or other ...
2012-06-08
Berlin, Germany, June 7 2012: A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
Via the Nationwide Inpatient Sample (NIS), 4.3 million patients over the age of 65 with osteoporotic hip fractures were studied. Results showed that 67.3% of hip fractures occurred in the extreme elderly, increasing from 172,209 in 1993 to 180,428 in 2008. This ...
2012-06-08
Berlin, Germany, June 7 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo.
This randomised, placebo controlled, 24 week period of an ongoing Phase III study of 409 patients indicated that more patients treated with both doses of CZP achieved ACR50* and ACR70* response ...
2012-06-08
Berlin, Germany, June 7 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab).
Results of the German study ...
2012-06-08
Berlin, Germany, June 7 2012: Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
"Anti-TNFs, such as infliximab, adalimumab and etanercept have become the treatment of choice for patients with inflammatory rheumatic diseases who ...
2012-06-08
Berlin, Germany, June 7 2012: Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20*.
The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) was carried out in 646 biologic-naïve patients with active RA and inadequate response to methotrexate. ...
2012-06-08
All nuclear energy and weapons programs should be independently regulated and subject to rigorous peer review, according to three experts on nuclear policy. Their comments and recommendations are published in an article entitled, "A Safer Nuclear Enterprise," in the June 8 issue of the journal Science.
The authors noted that, despite international diplomatic efforts to prevent the proliferation of nuclear weapons and ensure that nuclear material is protected against theft, there is growing apprehension about terrorists acquiring weapons or nuclear material.
"There is ...
LAST 30 PRESS RELEASES:
[Press-News.org] Report addresses challenges in implementing new diagnostic tests where they are needed most